Brief: Polypid Receives PDUFA Fee Waiver From FDA For D-Plex₁₀₀’S New Drug Application
17/03/2026 12:31
March 17 (Reuters) - PolyPid Ltd PYPD.O: POLYPID RECEIVES PDUFA FEE WAIVER FROM FDA FOR D-PLEX₁₀₀’S NEW DRUG APPLICATION POLYPID LTD - ON TRACK TO INITIATE NDA SUBMISSION FOR D-PLEX₁₀₀ BY END OF MARCH 2026 Source text: ID:nGNX7mm1yF Further company coverage: PYPD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA